Cosco - Testing Support Zone

Closing near 200EMA and lower support trendline.

Testing support zone $5.00 - $4.62

InvestBio’s Biotech Investments: We Invest in Tomorrow’s Biotech Companies Today

InvestBio has participated in the following biotech companies:

Alteon Inc.

Alteon Inc. is a product-based biopharmaceutical company engaged in the development of small-molecule drugs to reverse or slow down diseases of aging and complications of diabetes. The Company's lead compound, Alagebrium Chloride (formerly ALT-711), is in clinical development, and several others are in earlier development stages. These pharmaceutical candidates were developed as a result of Alteon's research on the Advanced Glycation End-Products (A.G.E.) pathway (a pathological process and inevitable consequence of aging that causes or contributes to many medical disorders, including cardiovascular, kidney, and eye diseases).

AmpliMed, Inc.

AmpliMed, Inc., a privately held, early stage biotechnology company, originated as a group of research projects within the Arizona Cancer Center (AZCC), part of the University of Arizona. In 1989 it became a separate company and focused on the development of therapeutic agents for high value oncology indications. AmpliMed, utilizing the research facilities at AZCC, operates as a virtual company with flexible expense margins. It currently has two lead oncology drug candidates, Imexon and AMP-53, in it's product pipeline. In April 2003 AmpliMed received an IND approval from the FDA for Imexon, a cyanoaziridine series compound. AmpliMed is now moving this drug candidate into clinical development at AZCC.

Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of drugs to treat multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and osteolytic bone disease, among other cancers. The Company's lead drug candidate, Atiprimod, is a small-molecule, orally available drug with antiproliferative and antiangiogenic activity. The Company was formed, in April 2003, through a reverse acquisition between Callisto Pharmaceuticals and Webtronics, Inc.

Kinexis, Inc.

Kinexis, Inc. is a start-up company focusing on the development of novel therapeutics and diagnostics for the treatment and prevention of CNS and GI motility disorders. Its strategy is to leverage a revenue-generating product stream through sponsored research and by forming relationships with major pharmaceutical and biotechnology companies. Kinexis seeks to build significant value early on in its formation and reduce major risk through partnering and diversifying. Their plan is to maintain low operating costs as a 'virtual' company, thereby, providing a solid foundation for long-term growth.

Trellis Bioscience, Inc.

Trellis Bioscience, Inc. is a venture backed biopharmaceutical company whose breakthrough technology for the discovery and optimization of peptide therapeutics enables a qualitatively new approach to inhibiting protein-protein interactions. Such interactions are central to most biological processes - from intracellular and extra cellular communication, to programmed cell death - and represent a large and important class of targets for human therapeutics. Despite the plethora of such targets that have been identified over the past decade, most drug discovery technologies have been unable to identify drug-like molecules that interfere with these interactions. Trellis has combined its proprietary multiplex detection technology with in-licensed technology from a prominent university laboratory, enabling the rapid generation of small, highly stable peptide scaffolds that potently and selectively block these important targets. Using this highly efficient platform the company will develop a pipeline of clinical candidates, with an initial focus in the discovery and development of cancer therapeutics.

The Vaccine Company

The Vaccine Company, a Delaware corporation formed in 2003, was founded to commercialize the PR1 vaccine developed at the M.D. Anderson Cancer Center at the University of Texas. The vaccine is currently in Phase I/II trials for relapsed refractory AML (acute myelogenous leukemia), CML (chronic myelogenous leukemia) failing current therapies and advanced myelodysplasia. The Vaccine Company has an exclusive worldwide license to the technology from the M.D. Anderson Cancer Center. The license includes exclusive rights to the PR1 vaccine and other potential peptide vaccines, which the company intends to advance to clinical trials. Regarding the current Phase I/II trials at present, the clinical response rate is 26% including hematological responses, cytogenetic remissions, and molecular remissions. The remissions are durable. There also seems to be a survival advantage in patients who had an immunological response, but no overt clinical response.

http://www.investbio.com/biotech_company.asp

developments in biotechnology

A Unique Time for Investors

Over the last ten years, developments in biotechnology have been significant and the future holds the potential for many cures and advancements in the medical world.
Biotechnology's impressive discoveries have made it a premier industry, it has:
Produced deep product pipelines
Demonstrated impressive revenue growth
Created life-saving drugs and treatments
Drawn qualified talent to the industry
Improved the regulatory environment
Gained strategic alignments with big pharma companies and governments organizations

http://www.investbio.com/biotech_investing.asp

How To Calculate Fibonaaci Time Cycles

There are a few software packages that have built in functions for avid Fibonacci users. The Fibonacci Trader and Miner’s Dynamic Trader are two packages that I have seen demonstrated. These packages assist the user in analyzing and projecting price and time targets using Fibonacci retracement or extension ratios, and time cycles. The user is able to break the analysis down to almost any intraday time period.

This article is to help traders learn how to project Fibonacci time cycles using an Excel spreadsheet or a Fibonacci time extension feature. The main difference between the features is that an Excel spreadsheet is based upon calendar days not trading days.

The following are some fundamentals that you need to understand. These fundamentals can be applied to any time frame, i.e. minute, daily, weekly or monthly chart.

Swing highs and lows may be easiest to determine using a bar chart.

Select major swing points. Major swing points tend to have more significance in the bigger picture.

Dates that are further apart between swing points have more meaning.

A confluence of projected dates is more reliable than a standalone date.

Dates one or two periods either side of the projected dates may be the actual date of a reversal.

Price must be moving in the direction of the current trend and be close to a high at the time of the projected date.

http://www.themoneyblogs.com/billw/my.blog/how-to-calculate-fibonaaci-time-cycles-.html